左心耳封堵预防房颤卒中的美国上市后经验
本研究评估了FDA批准左心耳封堵(LAAC)后美国所有病例的急性手术表现和并发症率。在3822例连续病例中,植入成功率为95.6%,中位手术时间50分钟,并发症率较低,包括心包填塞1.02%、手术相关卒中0.078%和手术相关死亡0.078%。尽管71%的术者为新术者,真实世界结果仍显示高成功率和低并发症率。
要点
- LAAC在美国上市后真实世界中植入成功率达95.6%,中位手术时间50分钟。
- 手术并发症率低:心包填塞1.02%,手术相关卒中0.078%,手术相关死亡0.078%。
- 71%的术者为新术者,其完成50%的手术,但总体结果良好。
核心结论
- 尽管大量术者此前无经验,LAAC上市后真实世界应用中手术成功率高且并发症率低。
研究设计与样本
- 研究获取了自2015年3月FDA批准以来美国所有LAAC手术的程序数据,共纳入3822例连续病例,由382名术者完成。
主要发现
- 植入成功3653例(95.6%),中位手术时间50分钟(范围10-210分钟)。
- 术者中71%为新术者(非临床试验术者),他们完成了50%的手术。
- 并发症包括心包填塞39例(1.02%)(24例经皮治疗,12例外科治疗,3例致命)、手术相关卒中3例(0.078%)、装置栓塞9例(0.24%)(6例需手术取出)、手术相关死亡3例(0.078%)。
临床怎么用
- 在临床实践中开展LAAC时,应关注手术并发症的预防和处理,尤其是心包填塞。
- 新术者经过适当培训后也可取得高成功率和低并发症率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Left atrial appendage closure (LAAC) was approved by the U.S. Food and Drug Administration (FDA) as a stroke prevention alternative to warfarin for patients with nonvalvular atrial fibrillation. However, clinical decision-making is confounded by the fact that although LAAC attenuates the anticoagulant-related lifetime risk of bleeding, implantation is associated with upfront complications. Thus, enthusiasm for LAAC as a treatment option has been appropriately tempered, particularly as the therapy is introduced beyond the clinical trial sites into general clinical practice. OBJECTIVES: This study evaluated the acute procedural performance and complication rates for all cases performed in the United States since FDA approval. METHODS: In the absence of a formal national clinical registry since regulatory approval in March 2015, we obtained procedural data on implantation procedures. Every LAAC procedure requires the presence of a manufacturer clinical specialist and for procedural parameter and periprocedural complication data to be collected using a standardized process and forms. RESULTS: In 3,822 consecutive cases, implantation was successful in 3,653 (95.6%), with a median procedure time of 50 min (range 10 to 210 min). Implanting physicians performing these procedures (n = 382) included 71% new, nonclinical trial implanters, who performed 50% of the procedures. Procedural complication rates included 39 pericardial tamponades (1.02%) (24 treated percutaneously, 12 surgically, and 3 fatal); 3 procedure-related strokes (0.078%); 9 device embolizations (0.24%) (6 requiring surgical removal); and 3 procedure-related deaths (0.078%). CONCLUSIONS: Despite a large fraction of previously inexperienced operators, in the real-world post-FDA approval experience of LAAC, procedural success was high and complication rates were low.
引用
- Reddy VY, Gibson DN, Kar S, et al. Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol. 2016. PMID: 27816552. doi:10.1016/j.jacc.2016.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。